Predict your next investment

Growth Equity
ewhealthcare.com

See what CB Insights has to offer

Investments

232

Portfolio Exits

73

Funds

15

Partners & Customers

3

About EW Healthcare Partners

EW Healthcare Partners is a venture capital firm pursuing investments in pharmaceuticals, biotechnology, medical devices, health care services and health information technology. EW Healthcare Partners has maintained its singular commitment to the healthcare industry and has been involved in the founding, investing, and/or management of healthcare companies ranging across all sectors, stages and geography.

EW Healthcare Partners Headquarter Location

75 Rockefeller Plaza Suite 1700A

New York, New York, 10019,

United States

646-429-1251

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest EW Healthcare Partners News

TherapeuticsMD Announces Expiration of Tender Offer

Jul 13, 2022

07/13/2022 | 06:51am EDT Message : Company anticipates termination of Merger Agreement with EW Healthcare Partners TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TXMD” or the “Company”) an innovative, leading women’s healthcare company, announced today that Athene Merger, Inc., an affiliate of EW Healthcare Partners (“EW”), did not acquire the required majority of shares of TXMD through the previously announced tender offer by the extended offer deadline of one minute after 11:59 PM Eastern Time on July 12, 2022. As a result, the tender offer has expired according to its terms. The Company anticipates that the Merger Agreement between TXMD and EW will be terminated pursuant to its terms following 11:59 PM Eastern Time on July 13, 2022. TherapeuticsMD intends to maintain normal operations at this time. TherapeuticsMD Advisors Greenhill & Co., LLC is serving as financial advisor and DLA Piper LLP (US) and Jones Day are serving as legal counsel to TherapeuticsMD. About TherapeuticsMD, Inc. TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. TherapeuticsMD’s products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. TherapeuticsMD is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about TherapeuticsMD, please visit https://www.therapeuticsmd.com/ or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD. Cautionary Notes Regarding Forward Looking Statements Certain statements in this communication, including, without limitation, statements regarding the proposed transaction, plans and objectives, and management’s beliefs, expectations or opinions, may contain forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements relate to future, not past, events and often address expected future actions and expected future business and financial performance. Forward-looking statements may be identified by the use of words such as “believe,” “will,” “should,” “estimate,” “anticipate”, “potential,” “expect,” “intend,” “plan,” “may,” “subject to,” “continues,” “if” and similar words and phrases. These forward-looking statements are not guarantees of future events and involve risks, uncertainties and assumptions that are difficult to predict. Actual results, developments and business decisions may differ materially from those expressed or implied in any forward-looking statements as a result of numerous factors, risks and uncertainties over which the Company has no control. These factors, risks and uncertainties include, but are not limited to, the following: whether the Company will be able to repay the indebtedness under the Company’s Financing Agreement, which is scheduled to mature on July 13, 2022, and, if not, whether the Company will be able to continue as a going concern; risks that the failure of the proposed transaction disrupts current plans and operations and potential difficulties in employee retention as a result of the failure of the proposed transaction; risks related to diverting management’s attention from ongoing business operations; the outcome of any legal proceedings that may be instituted related to the proposed transaction or the transaction agreement between the parties to the proposed transaction; the amount of the costs, fees, expenses and other charges related to the proposed transaction; general economic conditions, particularly those in the life science and medical device industries; stock trading prices, including the impact of the failure of the proposed transaction on the Company’s stock price, particularly in relation to the Company’s current and future capital needs and its ability to raise additional funds to finance its future operations; and other factors discussed from time to time in the reports of the Company filed with the Securities and Exchange Commission (the “SEC”), including the risks and uncertainties contained in the sections titled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s most recent Annual Report on Form 10-K, as filed with the SEC on March 23, 2022, and related sections in the Company’s subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, all of which are available free of charge at http://www.sec.gov or under the “Investors & Media” section on the Company’s website at www.therapeuticsmd.com . Forward-looking statements reflect the views and assumptions of management as of the date of this communication with respect to future events. The Company does not undertake, and hereby disclaims, any obligation, unless required to do so by applicable laws, to update any forward-looking statements as a result of new information, future events or other factors. The inclusion of any statement in this communication does not constitute an admission by the Company or any other person that the events or circumstances described in such statement are material. View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005369/en/ © Business Wire 2022

EW Healthcare Partners Investments

232 Investments

EW Healthcare Partners has made 232 investments. Their latest investment was in VitalConnect as part of their Series E on January 1, 2022.

CBI Logo

EW Healthcare Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/7/2022

Series E

VitalConnect

$39M

Yes

10

11/18/2020

Series D

COTA

$34M

Yes

6

9/11/2020

Unattributed VC

Metabolon

$21.77M

No

2

7/14/2020

Series H

Subscribe to see more

$99M

Subscribe to see more

10

7/2/2020

PIPE

Subscribe to see more

Subscribe to see more

10

Date

1/7/2022

11/18/2020

9/11/2020

7/14/2020

7/2/2020

Round

Series E

Series D

Unattributed VC

Series H

PIPE

Company

VitalConnect

COTA

Metabolon

Subscribe to see more

Subscribe to see more

Amount

$39M

$34M

$21.77M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

10

6

2

10

10

EW Healthcare Partners Portfolio Exits

73 Portfolio Exits

EW Healthcare Partners has 73 portfolio exits. Their latest portfolio exit was Suneva Medical on January 12, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

1/12/2022

Acq - Pending

$99M

1

12/21/2021

Acquired

$99M

1

10/29/2021

IPO

$99M

Public

4

10/14/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

2/17/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/12/2022

12/21/2021

10/29/2021

10/14/2021

2/17/2021

Exit

Acq - Pending

Acquired

IPO

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

1

1

4

10

10

EW Healthcare Partners Acquisitions

10 Acquisitions

EW Healthcare Partners acquired 10 companies. Their latest acquisition was Grundium on May 05, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

5/5/2022

Grant

$99M

$2.37M

Acq - Fin

2

4/30/2021

$99M

Acq - Fin

1

5/10/2012

Debt

$99M

$6M

Acq - Fin

5/9/2012

Subscribe to see more

$99M

Subscribe to see more

0

1/2/2012

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/5/2022

4/30/2021

5/10/2012

5/9/2012

1/2/2012

Investment Stage

Grant

Debt

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$2.37M

$6M

Note

Acq - Fin

Acq - Fin

Acq - Fin

Subscribe to see more

Subscribe to see more

Sources

2

1

0

10

EW Healthcare Partners Fund History

15 Fund Histories

EW Healthcare Partners has 15 funds, including EW Healthcare Partners Fund 2a.

Closing Date

Fund

Fund Type

Status

Amount

Sources

8/22/2019

EW Healthcare Partners Fund 2a

Multi-Stage Venture Capital

Closed

$746.33M

4

6/11/2019

Titan Co-Investment Fund 2

$27M

1

10/28/2016

Essex Woodlands Fund IX

Industry Focused

Closed

$543.1M

3

3/30/2009

Essex Woodlands Health Ventures VIII LP (consolidated)

Subscribe to see more

Subscribe to see more

$99M

10

5/18/2006

Essex Woodlands Health Ventures VII LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

8/22/2019

6/11/2019

10/28/2016

3/30/2009

5/18/2006

Fund

EW Healthcare Partners Fund 2a

Titan Co-Investment Fund 2

Essex Woodlands Fund IX

Essex Woodlands Health Ventures VIII LP (consolidated)

Essex Woodlands Health Ventures VII LP

Fund Type

Multi-Stage Venture Capital

Industry Focused

Subscribe to see more

Subscribe to see more

Status

Closed

Closed

Subscribe to see more

Subscribe to see more

Amount

$746.33M

$27M

$543.1M

$99M

$99M

Sources

4

1

3

10

10

EW Healthcare Partners Partners & Customers

3 Partners and customers

EW Healthcare Partners has 3 strategic partners and customers. EW Healthcare Partners recently partnered with Smith & Nephew on January 1, 2012.

Date

Type

Business Partner

Country

News Snippet

Sources

1/4/2012

Partner

United Kingdom

EW Healthcare Partners News - Essex Woodlands Announces Strategic Partnership with Smith & Nephew to Fund Spinout of Biologics and Clinical Therapies Division, Creating Leading Orthopedic Biologics Company

Pantheon Ventures , a Limited Partner of Essex Woodlands , and Spindletop Healthcare Capital may participate alongside Essex Woodlands in the investment .

5

1/4/2012

Partner

United Kingdom

Subscribe to see more

Subscribe to see more

10

1/4/2012

Partner

United Kingdom

Subscribe to see more

Subscribe to see more

10

Date

1/4/2012

1/4/2012

1/4/2012

Type

Partner

Partner

Partner

Business Partner

Country

United Kingdom

United Kingdom

United Kingdom

News Snippet

EW Healthcare Partners News - Essex Woodlands Announces Strategic Partnership with Smith & Nephew to Fund Spinout of Biologics and Clinical Therapies Division, Creating Leading Orthopedic Biologics Company

Pantheon Ventures , a Limited Partner of Essex Woodlands , and Spindletop Healthcare Capital may participate alongside Essex Woodlands in the investment .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

5

10

10

EW Healthcare Partners Team

21 Team Members

EW Healthcare Partners has 21 team members, including current Chief Financial Officer, Richard Kolodziejcyk.

Name

Work History

Title

Status

Marty Sutter

Founder

Current

Richard Kolodziejcyk

Chief Financial Officer

Current

Krista Sickles

Controller

Current

Brooks Andrews

Roark Capital Group, FFL Partners, Barclays Capital, and Lehman Brothers

Managing Director

Current

Scott Barry

Managing Director

Current

Name

Marty Sutter

Richard Kolodziejcyk

Krista Sickles

Brooks Andrews

Scott Barry

Work History

Roark Capital Group, FFL Partners, Barclays Capital, and Lehman Brothers

Title

Founder

Chief Financial Officer

Controller

Managing Director

Managing Director

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.